PFA Pension Forsikringsaktieselskab Buys Shares of 543,261 Edwards Lifesciences Corporation $EW

PFA Pension Forsikringsaktieselskab acquired a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 543,261 shares of the medical research company's stock, valued at approximately $46,829,000. PFA Pension Forsikringsaktieselskab owned approximately 0.09% of Edwards Lifesciences at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of EW. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company's stock worth $434,318,000 after purchasing an additional 4,108,270 shares in the last quarter. Viking Global Investors LP purchased a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $238,688,000. Jennison Associates LLC increased its stake in shares of Edwards Lifesciences by 19.6% during the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company's stock worth $1,085,574,000 after purchasing an additional 2,287,783 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Edwards Lifesciences by 8.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company's stock worth $1,478,425,000 after purchasing an additional 1,423,365 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Edwards Lifesciences by 114.5% during the 3rd quarter. AQR Capital Management LLC now owns 2,081,346 shares of the medical research company's stock worth $161,055,000 after purchasing an additional 1,111,139 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 22,680 shares of the business's stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total transaction of $1,818,028.80. Following the completion of the sale, the vice president directly owned 21,266 shares of the company's stock, valued at $1,704,682.56. The trade was a 51.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the business's stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the sale, the chief financial officer directly owned 39,699 shares of the company's stock, valued at $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 86,058 shares of company stock valued at $7,118,636 in the last ninety days. Company insiders own 0.31% of the company's stock.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of recent research reports. BTIG Research raised their price objective on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, April 24th. Mizuho set a $95.00 price objective on shares of Edwards Lifesciences and gave the stock an "outperform" rating in a research note on Monday, April 13th. Robert W. Baird raised their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a "neutral" rating in a research note on Friday, April 24th. Wolfe Research raised shares of Edwards Lifesciences from a "peer perform" rating to an "outperform" rating and set a $92.00 price objective for the company in a research note on Wednesday, April 1st. Finally, UBS Group reissued a "neutral" rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $95.65.

Edwards Lifesciences Stock Up 0.7%

Shares of NYSE EW opened at $84.08 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The firm has a market cap of $48.47 billion, a P/E ratio of 44.72, a price-to-earnings-growth ratio of 2.11 and a beta of 0.87. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $87.89. The firm's 50 day moving average price is $82.08 and its 200 day moving average price is $82.47.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.17%. The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same quarter last year, the firm posted $0.64 earnings per share. Edwards Lifesciences's revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.